News & Updates

In the treatment of Chinese patients with metabolic dysfunction-associated steatohepatitis (MASH) and F2 or F3 fibrosis, the use of the selective thyroid hormone receptor-β agonist simedeutirom helps improve disease activity without worsening of fibrosis, as shown in a phase IIb trial.

In patients with kidney failure who are undergoing haemodialysis, initiating treatment with apixaban soon after a diagnosis of atrial fibrillation (AF) is associated with lower risks of ischaemic stroke and clinically important bleeding compared with warfarin, according to a study.

Poisoning is a unique driver of healthcare utilization among patients receiving care at the emergency department (ED) in Singapore. The Singhealth Toxicology Service offers insights in the management of this cohort, helping to prevent harm and improve resource allocation.

Short-term safety does not significantly differ between ibuprofen and acetaminophen in paediatric and acute pain patients, a study has shown.

In patients with inflammatory arthritis, temporary interruption of biologic or Janus kinase inhibitor (JAKi) therapies during supplemental COVID-19 vaccination does not help improve humoral immunogenicity and even increases flare risk, as shown in the pragmatic COVER trial.

Three proton pump inhibitors (PPIs) demonstrate cardiovascular safety in patients with acute myocardial infarction (MI) receiving dual antiplatelet therapy (DAPT), according to a study. Moreover, use of lansoprazole contributes to a reduced risk of gastrointestinal bleeding.

Treatment with gildeuretinol acetate capsules helps slow the growth of retinal atrophic lesions in individuals with Stargardt disease, according to the phase II TEASE-1 trial.

Macrolide resistance mutations (MRMs) were detected in more than 40 percent of Mycoplasma (M.) genitalium infections among individuals aged 14-59 years in the US in 2017-2018, representing approximately 1.4 million macrolide-resistant infections.

In the treatment or non-cirrhotic patients with chronic hepatitis C virus (HCV) infection, an 8-week course of sofosbuvir–velpatasvir combination has similar efficacy to the standard 12-week course, according to the open-label RESOLVE trial.

A phase II trial has demonstrated the safety and tolerability of combination treatment with intravesical cabazitaxel, gemcitabine, and cisplatin in patients with nonmuscle-invasive bacillus Calmette-Guérin (BCG)‒unresponsive urothelial carcinoma of the bladder.